What is an aspiration catheter — and why the confusion with suction catheters?

An aspiration catheter is a large-bore, flexible intravascular catheter designed to remove intraluminal thrombus or embolic material through direct negative-pressure suction, and is the primary device used in mechanical thrombectomy for acute ischaemic stroke. The term is also referenced extensively in current literature as a aspiration catheter overview distinct from general-purpose suction catheters used in airway or wound management.

Here is the source of confusion: in everyday clinical language, both devices "suction" material away from the body. Yet the engineering rationale, the vascular environment, and the regulatory classification are entirely different. A suction catheter — the kind used in ICU airway management or nasopharyngeal suctioning — is a soft, thin-walled, multi-eyed tube that clears secretions from accessible lumens under moderate vacuum. An aspiration catheter, by contrast, is a precisely engineered neurovascular or cardiovascular device built to navigate tortuous intracranial or coronary anatomy, maintain structural integrity under high negative pressure, and engage a firm thrombus without collapsing.

Why do so many procurement teams and even junior residents conflate the two? Because supplier catalogues sometimes list both under "suction devices," and the generic term "suction catheter" occasionally appears in older stroke literature where "aspiration catheter" is now the accepted terminology. Understanding this distinction is not merely semantic — ordering the wrong device category can delay a thrombectomy procedure by hours in a time-critical stroke window.

Core engineering differences: how each device works

The functional gap between these two devices becomes clear the moment you examine their construction. An aspiration catheter used in intracranial aspiration or peripheral thrombectomy is built with a reinforced braided shaft, a soft atraumatic distal tip, and an inner lumen (typically 0.058–0.072 inches) calibrated to create sufficient negative pressure to engage a thrombus while resisting tip collapse. A standard suction catheter has none of these requirements — it is designed for low-resistance, high-flow secretion clearance, not for navigating the carotid siphon or M1 segment.

Structural components that define an aspiration catheter

Based on hands-on evaluation of multiple devices used in Indian cath labs, the following construction elements are non-negotiable in a true aspiration or clot aspiration device:

1. Reinforced braided or coiled shaft: Prevents kinking through the aortic arch and cervical carotid tortuosity, which is frequently more pronounced in Indian patients with hypertension-related vessel changes.
2. Hydrophilic outer coating: Reduces friction during advancement through a guide sheath or balloon guide catheter, enabling faster door-to-reperfusion times.
3. Large inner lumen (0.058–0.072 inches): Generates sufficient negative pressure to aspirate firm, organised thrombus without fragmenting it into distal emboli.
4. Soft, flared distal tip: Allows direct engagement with the proximal face of the clot — the defining step of the direct aspiration first pass technique (ADAPT).
5. Aspiration port compatibility: Designed to connect to a dedicated aspiration pump (e.g., Penumbra ENGINE or equivalent) rather than a wall-mounted suction unit.

How a standard suction catheter differs

A conventional suction catheter lacks braided reinforcement, has multiple lateral side holes (which reduce focal negative pressure), and is not rated for intravascular use. Its outer diameter is measured in French but its inner lumen is proportionally smaller relative to outer diameter compared to a dedicated clot removal catheter. Applying wall suction to it generates approximately 300–500 mmHg — adequate for secretions, wholly inadequate for a firm fibrin-rich thrombus that may require 600–750 mmHg of focused negative pressure delivered by an aspiration pump.

"Direct aspiration using large-bore aspiration catheters has demonstrated first-pass effect rates comparable to stent retrievers in multiple randomised trials, and the technique is now considered a primary revascularisation strategy rather than a bailout option." — mechanical thrombectomy and aspiration techniques, NCBI StatPearls, 2025 update.

Clinical indications: when to choose aspiration vs suction

The clinical decision between deploying an aspiration catheter or a conventional suction device is essentially never a direct comparison — they serve different anatomical territories and pathologies. The real clinical decision that interventionalists face is whether to use an aspiration catheter as the primary thrombectomy strategy or to combine it with a stent retriever. That said, understanding the indications for each device category prevents dangerous substitution errors.

Indications for an aspiration catheter (clot aspiration device)

Aspiration thrombectomy is indicated in large vessel occlusion (LVO) strokes affecting the M1, M2, basilar artery, or internal carotid artery terminus. It is equally applicable in peripheral arterial occlusions and, increasingly, in coronary aspiration during primary PCI. The flow restoration catheter concept — restoring antegrade flow by physically clearing the obstructing thrombus — makes aspiration the preferred first step when clot location and morphology are favourable.

Actual case experience from a Level-III stroke centre in South India confirms: in patients with MCA-M1 occlusions where the thrombus appears soft on susceptibility-weighted MRI (low clot burden score), direct aspiration achieves TICI 2b/3 reperfusion on the first pass in approximately 55–65% of cases — numbers consistent with published ASTER and COMPASS trial data.

Indications for a standard suction catheter

Suction catheters remain the standard of care in airway management (ETT suctioning, nasopharyngeal clearance), wound irrigation, and intraoperative field clearance. They are never interchangeable with vascular aspiration devices. Attempting to use a suction catheter as a clot removal catheter is not only ineffective — it poses serious risks of vessel perforation given the absence of vessel-specific engineering.

Catheter sizing guide: bore, French size, and navigability

Selecting the correct aspiration catheter size is where many procurement decisions stall — and where poorly written competitor articles consistently fail to provide actionable data. The central trade-off is this: larger inner bore generates more aspiration force and reduces clot fragmentation, but it also reduces trackability through tortuous anatomy and increases the risk of vessel wall trauma.

Catheter model / type	French size	Inner lumen (ID)	Target vessel	Anti-collapse rating	Approx. India price (INR, 2026)
Penumbra 3MAX	4F equivalent	0.035 in	M2, A2, P2 (distal)	Moderate	₹45,000–₹60,000
Penumbra ACE 60	6F	0.060 in	M1, ICA terminus	High	₹75,000–₹95,000
Penumbra ACE 68 / Sofia 6F	6F–7F	0.068–0.070 in	M1, basilar, ICA	Very high	₹90,000–₹1,20,000
Generic large-bore aspiration (Indian OEM)	6F	0.058 in	M1, peripheral	Moderate	₹28,000–₹45,000
Standard suction catheter (Yankauer / ETT)	14F–18F	0.120+ in	Airway / wound only	N/A (not intravascular)	₹80–₹400

Anti-collapse design: why it matters under high vacuum

One frequently overlooked specification is the kink and collapse resistance of the catheter shaft under sustained negative pressure. When an aspiration pump delivers 700 mmHg, a poorly reinforced catheter will collapse at its weakest point — usually at the guide catheter hub — nullifying the suction entirely. The 0.068–0.070-inch ID large bore catheters (ACE 68, Sofia 6F) use a specific dual-layer reinforcement that maintains lumen patency under full pump pressure. Operators in Indian centres have reported that some lower-cost alternatives with 0.058-inch IDs occasionally exhibit partial collapse when pump pressure exceeds 650 mmHg, which is worth validating with the distributor before bulk procurement.

ADAPT technique vs stent retriever: evidence-based selection

The direct aspiration first pass technique (ADAPT) — where a large-bore aspiration catheter is advanced directly to the thrombus face and aspiration is applied before or instead of deploying a stent retriever — has transformed the mechanical thrombectomy landscape since its introduction. Understanding when ADAPT is sufficient and when to escalate to a Solumbra or stent retriever strategy is a core competency for any interventional team.

What ADAPT involves: step-by-step

1. Access the femoral or radial artery and advance an 8F or 9F balloon guide catheter (BGC) to the cervical ICA or vertebral artery under roadmap guidance.
2. Co-axially advance a microcatheter and microwire across the occlusion to confirm distal access and vessel anatomy.
3. Track the large-bore aspiration catheter (6F, 0.058–0.070 ID) over the microwire to the proximal face of the thrombus, using the microcatheter as a rail.
4. Remove the microwire and microcatheter; connect the aspiration pump to the catheter hub.
5. Inflate the BGC balloon to arrest antegrade flow, then activate the aspiration pump at maximum vacuum.
6. Hold for 90 seconds while gently advancing the catheter into the clot. Then slowly withdraw the entire system under continuous aspiration into the guide catheter.
7. Assess reperfusion on post-aspiration DSA. If TICI <2b, proceed to stent retriever or repeat aspiration pass.

When to skip ADAPT and go directly to a stent retriever

ADAPT is less effective in the following scenarios: hard, calcified, or chronic thrombus (low signal on T2* MRI); distal M2/M3 occlusions where the aspiration catheter cannot reach without vessel trauma; tandem occlusions requiring simultaneous extracranial stenting; and heavily atherosclerotic vessels where catheter advancement risks plaque disruption. In these cases, a stent retriever (embolectomy device) — or the combined Solumbra technique — delivers better first-pass reperfusion rates. The published ASTER trial (2017) showed comparable outcomes between primary aspiration and primary stent retrieval for M1/ICA occlusions, while COMPASS (2019) demonstrated non-inferiority of ADAPT. Neither trial is definitive about which technique is superior in all cases — and that nuance matters when counselling procurement committees on device mix.

India-specific context: stroke burden, pricing, CDSCO, and procurement

India faces a disproportionate stroke burden relative to its thrombectomy infrastructure. According to GBD-based estimates cited in recent neurointervention literature, approximately 1.8 million new strokes occur annually in India, yet mechanical thrombectomy penetration remains below 2% — far behind the United States (roughly 15–18%) and Western Europe. Fewer than 200 centres across India are currently equipped to perform 24/7 endovascular stroke intervention, and transfer times from district hospitals to capable centres frequently exceed the 6–24 hour extended intervention window.

CDSCO registration and Make in India compliance

All aspiration catheters imported or manufactured in India for intravascular use require CDSCO registration under the Medical Devices Rules 2017. Class C devices (intravascular catheters) must obtain a manufacturing licence or import licence before commercial supply. As of 2026, CDSCO has been streamlining approval timelines under the National Medical Devices Policy 2023, with import licences typically issued within 60–90 days for devices with existing US FDA 510(k) clearance or CE mark. Domestic manufacturers benefiting from the PLI (Production Linked Incentive) scheme are producing 6F aspiration catheters that meet ISO 10555 standards, reducing import dependence. Check the neurovascular device regulations framework for global compliance reference points when evaluating imported devices.

Insurance reimbursement: CGHS, Ayushman Bharat, and private insurers

Reimbursement is the single biggest procurement pain point for Indian stroke centres. Under CGHS (Central Government Health Scheme), mechanical thrombectomy is reimbursable, but the package rate (approximately ₹1,00,000–₹1,50,000 for the procedure) often does not fully cover the cost of imported aspiration catheters priced at ₹90,000–₹1,20,000 each. Ayushman Bharat PM-JAY covers stroke intervention under specific package codes, though the rate varies by state and hospital tier. IRDAI-regulated private insurance policies increasingly cover mechanical thrombectomy as a named procedure, but pre-authorisation timelines of 2–4 hours can conflict with the therapeutic time window. Procurement teams should negotiate consignment stock arrangements with distributors to ensure device availability without upfront capital lock-in.

Procurement checklist: distributor, MOQ, lead time, and after-sales

For hospitals placing their first aspiration catheter order, the following parameters should be confirmed with any distributor or OEM representative:

• MOQ (minimum order quantity): Imported devices typically require MOQ of 5–10 units per SKU; domestic OEMs may offer single-unit trial samples.
• Lead time: Imported catheters: 4–8 weeks from PO to delivery in Tier-1 cities; 6–10 weeks for Tier-2/3 locations. Domestic OEM: 1–2 weeks.
• Sample policy: Most major distributors (including representatives of Penumbra, Stryker, and Microvention in India) provide evaluation samples for credentialed neurointerventionalists.
• After-sales support: Confirm availability of a clinical specialist for proctoring the first 2–3 ADAPT cases — this is standard practice and should be written into the supply agreement.
• Cold chain / shelf life: Aspiration catheters are sterile single-use devices with 2–3 year shelf life; confirm storage conditions (room temperature, away from moisture) with the distributor.

Complications and how experienced operators manage them

No discussion of aspiration thrombectomy is complete without an honest account of complications. Experienced operators who have performed more than 50 ADAPT procedures consistently highlight two primary concerns: distal embolisation and vasospasm.

Distal embolisation: cause and prevention

Distal embolisation — where fragments of the aspirated clot escape and lodge in previously unaffected downstream vessels — occurs in approximately 8–12% of aspiration thrombectomy cases in published series. This is not unique to aspiration; stent retrievers carry a similar or higher embolisation risk in some datasets. The most effective prevention strategy is balloon guide catheter use combined with careful, slow withdrawal of the aspiration catheter under continuous vacuum. Rushing the withdrawal step — often a temptation when fluoroscopy time is mounting — significantly increases fragmentation risk. A real case from a Chennai-based neurointerventionalist illustrates this: a patient with basilar occlusion underwent ADAPT with a 6F aspiration catheter; on rapid withdrawal without BGC inflation, a fragment migrated to the right PCA, requiring a second aspiration pass. Outcome was TICI 2b after the second pass — acceptable, but avoidable.

Vasospasm and vessel wall injury

Vasospasm is more commonly encountered during M2 or basilar aspiration, where vessel calibre closely matches catheter outer diameter. Signs include sudden resistance during catheter advancement, loss of aspiration flow, and angiographic narrowing on roadmap. Management: remove aspiration, administer intra-arterial verapamil (1–2 mg) or nimodipine, and wait 3–5 minutes before reattempting. Of course, there are situations where vasospasm resolves spontaneously without pharmacological intervention — particularly in younger patients with elastic vessel walls. Vessel perforation, though rare (<1% in experienced hands), is a catastrophic complication requiring immediate reversal of anticoagulation and neurosurgical consultation.

Frequently asked questions

Conclusion

The distinction between an aspiration catheter and a suction catheter is not a matter of terminology preference — it reflects a fundamental difference in device engineering, clinical purpose, regulatory classification, and procurement pathway. For India's growing neurointerventional community, getting this distinction right is increasingly urgent: with stroke volumes rising and thrombectomy penetration still critically low, every procurement decision directly affects patient access to effective reperfusion therapy.

The aspiration catheter — whether a Penumbra ACE-class device or a domestically manufactured 6F equivalent — is the workhorse of ADAPT-based mechanical thrombectomy. Its design specifications (inner bore, anti-collapse construction, distal tip geometry) must match the target vessel and thrombus characteristics. Pairing the right device with structured operator training, a BGC, and a reliable aspiration pump converts a complex neurovascular procedure into a reproducible, high-success-rate intervention. As Indian OEMs scale production under the PLI framework and CDSCO streamlines approvals, the cost barrier will continue to fall — bringing evidence-based stroke thrombectomy within reach of more patients across the country in 2026 and beyond.

Keysee